Disruptions in effort-based decision-making and consummatory behavior following antagonism of the dopamine D2

Cindee F Robles1, Alexander W Johnson1

  • 1Department of Psychology and Neuroscience Program, Michigan State University, East Lansing, MI 48824, United States.

Behavioural Brain Research
|December 17, 2016
PubMed

Insights

Blocking dopamine D2 receptors with eticlopride reduced mice's motivation for rewards. This neurotransmitter impacts effort-based decisions and consumption, highlighting its role in reward-seeking behaviors.

Area of Science:

  • Neuroscience
  • Behavioral Science
  • Pharmacology

Background:

  • Dopamine is implicated in motivation, but its exact function in decision-making and consumption is debated.
  • Dopamine D2 receptors are key targets for understanding these motivational processes.

Purpose of the Study:

  • To investigate the role of dopamine D2 receptor signaling in effort-based decision-making and reward consumption.
  • To characterize how eticlopride, a D2 receptor antagonist, affects motivated behaviors in mice.

Main Methods:

  • Mice were infused centrally with eticlopride (a dopamine D2 receptor antagonist) at varying doses.
  • Effort-based decision-making was assessed using a two-lever choice task with different sucrose reward values and response requirements.
  • Consummatory behavior was measured by intake of sucrose solution, with licking microstructure analyzed.

Main Results:

  • Eticlopride administration biased choice away from high-value rewards and towards low-value rewards as effort increased.
  • Higher eticlopride doses increased response omissions for high-value rewards.
  • Eticlopride dose-dependently reduced sucrose intake, primarily by decreasing motivation to consume, not reward evaluation.

Conclusions:

  • Disrupting dopamine D2 receptor signaling diminishes the motivation for effortful operant responding and consumption of desirable outcomes.
  • These findings underscore the critical role of D2 receptor pathways in regulating motivated behaviors and reward processing.

Related Concept Videos

Drugs Affecting Neurotransmitter Synthesis01:29

Drugs Affecting Neurotransmitter Synthesis

Drugs affecting neurotransmitter synthesis can impact the adrenergic neuron and the synthesis of neurotransmitters. For example, α-methyltyrosine and carbidopa target specific enzymes involved in catecholamine synthesis. α-methyltyrosine inhibits the enzyme tyrosine hydroxylase, which converts tyrosine into dopamine. By blocking this enzyme, α-methyltyrosine reduces dopamine production and other catecholamines. Carbidopa, on the other hand, inhibits the enzyme dopa decarboxylase,...
2.4K
Adrenergic Agonists: Indirect-Acting Agents01:25

Adrenergic Agonists: Indirect-Acting Agents

Indirect-acting adrenergic agonists potentiate the effects of endogenous catecholamines through different mechanisms without directly binding to adrenoceptors.
One mechanism involves depleting stored catecholamines by displacing them from synaptic vesicles. These agents, known as "displacers," are transported into vesicles at the expense of noradrenaline. Examples include amphetamine and tyramine, which lack a catechol moiety, resulting in prolonged action, improved oral...
2.9K
Drugs Affecting GI Tract Motility: Dopamine Receptor Antagonists01:28

Drugs Affecting GI Tract Motility: Dopamine Receptor Antagonists

Prokinetic agents are specialized medications that stimulate gastrointestinal (GI) motility, promoting food movement through the GI tract. Dopamine, an inhibitory neurotransmitter, plays a significant role in this process, reducing GI motility and indirectly controlling the speed of digestion. Dopamine receptor antagonists, such as metoclopramide and domperidone, offer a unique advantage as prokinetic agents. By blocking the dopamine receptors, these drugs increase GI motility, improving food...
1.6K
Drugs Affecting Neurotransmitter Release or Uptake01:21

Drugs Affecting Neurotransmitter Release or Uptake

Certain drugs can affect how neurotransmitters called catecholamines, are released or taken back up in the adrenergic neuron. They can have different effects on the body's sympathetic transmission. Reserpine, a natural compound found in the Rauwolfia shrub, blocks a transporter called vesicular monoamine transporter (VMAT), which leads to a buildup of catecholamines in the cell and reduces sympathetic transmission. Another drug called guanethidine works in multiple ways, including blocking...
1.7K